ArticleRMD open2018
DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs.
Article in RMD open, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.Current rheumatology reports · 2026Review
- Development and validation of a new ultrasound score (SONAR-7) for synovitis in psoriatic arthritis and axial spondyloarthritis.RMD open · 2026Article
- Clinical and ultrasonographic features preceding a difficult-to-treat phenotype in psoriatic arthritis: a retrospective real-world exploratory cohort study.Frontiers in immunology · 2026Article
- Entheseal Doppler signals in ultrasound are associated with vasodilator drugs and age in patients with radiographic axial spondyloarthritis.Arthritis research & therapy · 2025Article
- Practical Use of Ultrasound in Modern Rheumatology-From A to Z.Life (Basel, Switzerland) · 2024Review
- Additional Value of Ultrasound in Patients with Psoriatic Arthritis within Treatment Target.Journal of clinical medicine · 2024Article
- Difficult to treat psoriatic arthritis - how should we manage?Clinical rheumatology · 2023Review
- A Narrative Review of the Design of Ultrasound Indices for Detecting Enthesitis.Diagnostics (Basel, Switzerland) · 2022Review
- Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study.Clinical rheumatology · 2022Observational
- Residual inflammation in psoriatic arthritis patients in stable minimal disease activity.Frontiers in medicine · 2022Article
- Ultrasound shows swollen joints are the better proxy for synovitis than tender joints in DMARD-naïve early psoriatic arthritis.Rheumatology advances in practice · 2021Article
- Recent Advances in Imaging for Diagnosis, Monitoring, and Prognosis of Psoriatic Arthritis.Frontiers in medicine · 2020Review
- Ultrasound Imaging in Psoriatic Arthritis: What Have We Learnt in the Last Five Years?Frontiers in medicine · 2020Review
- Clinical and Ultrasound Assessment of Enthesis in Psoriatic Arthritis in a Romanian Cohort.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesDisease Activity index for PSoriatic Arthritis (DAPSA) (sum score 68/66 tender/swollen joint counts (68TJC/66SJC), patient's global assessment, pain and C-reactive protein (CRP)) is recommended for clinical assessment of disease activity in patients with psoriatic arthritis (PsA). Ultrasound (US) (grey scale (GS) and power Doppler (PD)) detects inflammation in joints and extra-articular structures. The present objectives were to explore the longitudinal relationships between DAPSA, clinical assessment as well as patient-reported outcome measures (PROMs) with US in patients with PsA initiating biological DMARDs and the associations between DAPSA and US remission.
methods47 patients with PsA were examined at baseline and after 3, 6, 9 and 12 months. Assessments included 68TJC/66SJC, examiner's global assessment (EGA), PROMs, CRP, erythrocyte sedimentation rate (ESR) and US GS and PD (48 joints, 10 flexor tendons, 14 entheses, 4 bursae). Clinical composite scores and PD sum scores (0=remission) were calculated. Longitudinal associations were explored by generalised estimating equations with linear and logistic regression.
resultsDAPSA was not longitudinally associated to PD. 66SJC, ESR, 28-joint Disease Activity Score, EGA and CRP were longitudinally associated with PD (p<0.001-0.03), whereas the pain-related components of DAPSA (68TJC and pain) as well as PROMs were not associated. At 6-12 months, remission was achieved in 29%-33 % of the patients for DAPSA and 59%-70 % for PD. The association between DAPSA and PD remission was not significant (p=0.33).
conclusionsDAPSA was not associated with US inflammatory findings which indicates that DAPSA and US may assess different aspects of PsA activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.